TY - JOUR
T1 - Development and Validation of a Model to Predict Posttraumatic Stress Disorder and Major Depression after a Motor Vehicle Collision
AU - Ziobrowski, Hannah N.
AU - Kennedy, Chris J.
AU - Ustun, Berk
AU - House, Stacey L.
AU - Beaudoin, Francesca L.
AU - An, Xinming
AU - Zeng, Donglin
AU - Bollen, Kenneth A.
AU - Petukhova, Maria
AU - Sampson, Nancy A.
AU - Puac-Polanco, Victor
AU - Lee, Sue
AU - Koenen, Karestan C.
AU - Ressler, Kerry J.
AU - McLean, Samuel A.
AU - Kessler, Ronald C.
AU - Stevens, Jennifer S.
AU - Neylan, Thomas C.
AU - Clifford, Gari D.
AU - Jovanovic, Tanja
AU - Linnstaedt, Sarah D.
AU - Germine, Laura T.
AU - Rauch, Scott L.
AU - Haran, John P.
AU - Storrow, Alan B.
AU - Lewandowski, Christopher
AU - Musey, Paul I.
AU - Hendry, Phyllis L.
AU - Sheikh, Sophia
AU - Jones, Christopher W.
AU - Punches, Brittany E.
AU - Lyons, Michael S.
AU - Murty, Vishnu P.
AU - McGrath, Meghan E.
AU - Pascual, Jose L.
AU - Seamon, Mark J.
AU - Datner, Elizabeth M.
AU - Chang, Anna M.
AU - Pearson, Claire
AU - Peak, David A.
AU - Jambaulikar, Guruprasad
AU - Merchant, Roland C.
AU - Domeier, Robert M.
AU - Rathlev, Niels K.
AU - O'Neil, Brian J.
AU - Sergot, Paulina
AU - Sanchez, Leon D.
AU - Bruce, Steven E.
AU - Pietrzak, Robert H.
AU - Joormann, Jutta
AU - Barch, Deanna M.
AU - Pizzagalli, Diego A.
AU - Sheridan, John F.
AU - Harte, Steven E.
AU - Elliott, James M.
AU - Van Rooij, Sanne J.H.
N1 - Funding Information:
Recovery After Trauma (AURORA) is supported by grant U01MH110925 from the NIMH, the US Army Medical Research and Material Command, the One Mind Foundation, and The Mayday Fund. Verily Life Sciences and Mindstrong Health provided some of the hardware and software used to perform study assessments. Support for title page creation and format was provided by AuthorArranger, a tool developed at the National Cancer Institute.
Funding Information:
reported receiving grants from National Institute of Mental Health (NIMH) during the conduct of the study. Dr An reported receiving grants from the NIMH, US Army Medical Research and Material Command, The One Mind Foundation, and The Mayday Fund and nonfinancial technical support in collecting and processing smartphone and smartwatch data from Verily Life Science and Mindstrong Health during the conduct of the study. Dr Sampson reported receiving grants from the NIMH during the conduct of the study. Dr Lee reported receiving grants from the NIMH during the conduct of the study. Dr Ressler reported receiving grants from Takeda and Brainsway and personal fees from Janssen, Verily, Alto Neuroscience, and Bioxcel outside the submitted work. Dr McLean reported receiving grants from the NIMH, Mindstrong Health, and Verily Life Sciences during the conduct of the study. Dr Kessler reported receiving grants from the NIMH, receiving consulting fees from DataStat Inc and Sage Pharmaceuticals, and owning stock in Mirah, PYM, and Roga Sciences during the conduct of the study. Dr Clifford reported receiving grants from University of North Carolina as a subcontract on the parent AURORA grant funding during the conduct of the study and in the past 3 years has received research funding from the National Science Foundation, National Institutes of Health (NIH), and LifeBell AI and unrestricted donations from AliveCor, Amazon Research, Center for Discovery, the Gordon and Betty Moore Foundation, MathWorks, Microsoft Research, Gates Foundation, Google, One Mind Foundation, and Samsung Research. Dr Clifford also has financial interest in AliveCor and receives unrestricted funding from the company and is the chief technical officer of MindChild Medical and the chief security officer of LifeBell AI and has ownership in both companies. Dr Jovanovic reported receiving grants from NIH during the conduct of the study and outside the submitted work. Dr Germine reported serving on the Scientific Advisory Board for Sage Bionetworks for which she receives a small honorarium. Dr Rauch reported receiving grants from NIH during the conduct of the study and grants from NIH, personal fees from Society of Biological Psychiatry, royalties from Oxford University Press and APP, a per diem for serving on the oversight committee of the Veterans Affairs, funds for board service from Community Psychiatry, including equity outside the submitted work, and having leadership roles on boards or councils for Society of Biological Psychiatry, Anxiety and Depression Association of America, and National Network of Depression Centers outside the submitted work. Dr Storrow reported receiving grants from NIH during the conduct of the study. Dr Sheikh reported receiving grants from Florida Medical Malpractice Joint Underwriter’s Association, Substance Abuse and Mental Health Services Administration, Florida Blue Foundation, and NIH/National Institute on Aging– funded Jacksonville Aging Studies Center outside the submitted work. Dr Jones reported receiving grants from NIMH during the conduct of the study and grants from Vapotherm Inc, Janssen, AstraZeneca, and Hologic Inc outside the submitted work. Dr Lyons reported receiving grants from NIH during the conduct of the study. Dr Pascual reported receiving grants from Grifols SA and personal fees for expert testimony outside the submitted work. Dr Chang reported receiving grants from NIH during the conduct of the study and personal fees from Roche and grants from Abbott, Ortho Clinical Diagnostics, and Siemens outside the submitted work. Dr Pearson reported receiving grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases during the conduct of the study. Dr Bruce reported receiving grants from NIMH during the conduct of the study. Dr Joormann reported receiving personal fees from Janssen Pharmaceuticals outside the submitted work. Dr Barch reported receiving grants from National Institute of Drug Abuse and NIMH during the conduct of the study. Dr Pizzagalli reported receiving personal fees from BlackThorn Therapeutics, Boehringer Ingelheim, Compass Pathways, Concert Pharmaceuticals, Engrail Therapeutics, Neurocrine Biosciences, Otsuka Pharmaceuticals, Takeda Pharmaceuticals, and Alkermes, receiving grants from Millennium Pharmaceuticals, NIMH, Brain and Behavior Research Foundation, and Dana Foundation, and having stock options in BlackThorn Therapeutics outside the submitted work. Dr Harte reported receiving grants from Aptinyx, Arbor Medical Innovations, and NIH and personal fees from Eli Lilly outside the submitted work. Dr Elliott reported receiving personal fees from Orofacial Therapeutics Honorarium outside the submitted work. No other disclosures were reported.
Publisher Copyright:
© 2021 American Medical Association. All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - Importance: A substantial proportion of the 40 million people in the US who present to emergency departments (EDs) each year after traumatic events develop posttraumatic stress disorder (PTSD) or major depressive episode (MDE). Accurately identifying patients at high risk in the ED would facilitate the targeting of preventive interventions. Objectives: To develop and validate a prediction tool based on ED reports after a motor vehicle collision to predict PTSD or MDE 3 months later. Design, Setting, and Participants: The Advancing Understanding of Recovery After Trauma (AURORA) study is a longitudinal study that examined adverse posttraumatic neuropsychiatric sequalae among patients who presented to 28 US urban EDs in the immediate aftermath of a traumatic experience. Enrollment began on September 25, 2017. The 1003 patients considered in this diagnostic/prognostic report completed 3-month assessments by January 31, 2020. Each patient received a baseline ED assessment along with follow-up self-report surveys 2 weeks, 8 weeks, and 3 months later. An ensemble machine learning method was used to predict 3-month PTSD or MDE from baseline information. Data analysis was performed from November 1, 2020, to May 31, 2021. Main Outcomes and Measures: The PTSD Checklist for DSM-5 was used to assess PTSD and the Patient Reported Outcomes Measurement Information System Depression Short-Form 8b to assess MDE. Results: A total of 1003 patients (median [interquartile range] age, 34.5 [24-43] years; 715 [weighted 67.9%] female; 100 [weighted 10.7%] Hispanic, 537 [weighted 52.7%] non-Hispanic Black, 324 [weighted 32.2%] non-Hispanic White, and 42 [weighted 4.4%] of non-Hispanic other race or ethnicity were included in this study. A total of 274 patients (weighted 26.6%) met criteria for 3-month PTSD or MDE. An ensemble machine learning model restricted to 30 predictors estimated in a training sample (patients from the Northeast or Midwest) had good prediction accuracy (mean [SE] area under the curve [AUC], 0.815 [0.031]) and calibration (mean [SE] integrated calibration index, 0.040 [0.002]; mean [SE] expected calibration error, 0.039 [0.002]) in an independent test sample (patients from the South). Patients in the top 30% of predicted risk accounted for 65% of all 3-month PTSD or MDE, with a mean (SE) positive predictive value of 58.2% (6.4%) among these patients at high risk. The model had good consistency across regions of the country in terms of both AUC (mean [SE], 0.789 [0.025] using the Northeast as the test sample and 0.809 [0.023] using the Midwest as the test sample) and calibration (mean [SE] integrated calibration index, 0.048 [0.003] using the Northeast as the test sample and 0.024 [0.001] using the Midwest as the test sample; mean [SE] expected calibration error, 0.034 [0.003] using the Northeast as the test sample and 0.025 [0.001] using the Midwest as the test sample). The most important predictors in terms of Shapley Additive Explanations values were symptoms of anxiety sensitivity and depressive disposition, psychological distress in the 30 days before motor vehicle collision, and peritraumatic psychosomatic symptoms. Conclusions and Relevance: The results of this study suggest that a short set of questions feasible to administer in an ED can predict 3-month PTSD or MDE with good AUC, calibration, and geographic consistency. Patients at high risk can be identified in the ED for targeting if cost-effective preventive interventions are developed.
AB - Importance: A substantial proportion of the 40 million people in the US who present to emergency departments (EDs) each year after traumatic events develop posttraumatic stress disorder (PTSD) or major depressive episode (MDE). Accurately identifying patients at high risk in the ED would facilitate the targeting of preventive interventions. Objectives: To develop and validate a prediction tool based on ED reports after a motor vehicle collision to predict PTSD or MDE 3 months later. Design, Setting, and Participants: The Advancing Understanding of Recovery After Trauma (AURORA) study is a longitudinal study that examined adverse posttraumatic neuropsychiatric sequalae among patients who presented to 28 US urban EDs in the immediate aftermath of a traumatic experience. Enrollment began on September 25, 2017. The 1003 patients considered in this diagnostic/prognostic report completed 3-month assessments by January 31, 2020. Each patient received a baseline ED assessment along with follow-up self-report surveys 2 weeks, 8 weeks, and 3 months later. An ensemble machine learning method was used to predict 3-month PTSD or MDE from baseline information. Data analysis was performed from November 1, 2020, to May 31, 2021. Main Outcomes and Measures: The PTSD Checklist for DSM-5 was used to assess PTSD and the Patient Reported Outcomes Measurement Information System Depression Short-Form 8b to assess MDE. Results: A total of 1003 patients (median [interquartile range] age, 34.5 [24-43] years; 715 [weighted 67.9%] female; 100 [weighted 10.7%] Hispanic, 537 [weighted 52.7%] non-Hispanic Black, 324 [weighted 32.2%] non-Hispanic White, and 42 [weighted 4.4%] of non-Hispanic other race or ethnicity were included in this study. A total of 274 patients (weighted 26.6%) met criteria for 3-month PTSD or MDE. An ensemble machine learning model restricted to 30 predictors estimated in a training sample (patients from the Northeast or Midwest) had good prediction accuracy (mean [SE] area under the curve [AUC], 0.815 [0.031]) and calibration (mean [SE] integrated calibration index, 0.040 [0.002]; mean [SE] expected calibration error, 0.039 [0.002]) in an independent test sample (patients from the South). Patients in the top 30% of predicted risk accounted for 65% of all 3-month PTSD or MDE, with a mean (SE) positive predictive value of 58.2% (6.4%) among these patients at high risk. The model had good consistency across regions of the country in terms of both AUC (mean [SE], 0.789 [0.025] using the Northeast as the test sample and 0.809 [0.023] using the Midwest as the test sample) and calibration (mean [SE] integrated calibration index, 0.048 [0.003] using the Northeast as the test sample and 0.024 [0.001] using the Midwest as the test sample; mean [SE] expected calibration error, 0.034 [0.003] using the Northeast as the test sample and 0.025 [0.001] using the Midwest as the test sample). The most important predictors in terms of Shapley Additive Explanations values were symptoms of anxiety sensitivity and depressive disposition, psychological distress in the 30 days before motor vehicle collision, and peritraumatic psychosomatic symptoms. Conclusions and Relevance: The results of this study suggest that a short set of questions feasible to administer in an ED can predict 3-month PTSD or MDE with good AUC, calibration, and geographic consistency. Patients at high risk can be identified in the ED for targeting if cost-effective preventive interventions are developed.
UR - http://www.scopus.com/inward/record.url?scp=85114496508&partnerID=8YFLogxK
U2 - 10.1001/jamapsychiatry.2021.2427
DO - 10.1001/jamapsychiatry.2021.2427
M3 - Article
C2 - 34468741
AN - SCOPUS:85114496508
SN - 2168-622X
VL - 78
SP - 1228
EP - 1237
JO - JAMA psychiatry
JF - JAMA psychiatry
IS - 11
ER -